Asset
TARCOCIMAB TEDROMER
KODIAK SCIENCES INC COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04964089 | phase3 | completed | 2021-06-23 | 2023-03-28 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) |
| NCT05066230 | phase3 | terminated | 2021-09-07 | 2023-08-03 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) |
| NCT04049266 | phase2_3 | terminated | 2019-10-08 | 2021-11-17 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. |
| NCT06556368 | phase3 | active_not_recruiting | 2024-08-23 | 2026-08-01 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK |
| NCT04603937 | phase3 | terminated | 2020-09-30 | 2023-04-27 | Kodiak Sciences Inc | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) |
FDA applications (0)
This company has no applications containing this asset.